Cancer is the second-leading cause of death in the United States, surpassed only by heart disease. But recent technological developments offer the hope of new and better ways to combat the disease.
For many of the most pervasive types of cancer, about half of the drug candidates furthest along in the research pipeline use approaches other than that of traditional cytotoxic drugs, which work by killing cells or preventing their division.
With continuing advances in the development of therapies like monoclonal antibodies and tumor vaccines, biotechnology should account for a growing portion of the cancer drug market, which may reach $80 billion a year by 2009.
As costs soar and reimbursement wanes, though, many patients are unlikely to reap the benefits of some of the most promising of these developments.
The new version of GPT-3 is much better behaved (and should be less toxic)
OpenAI has trained its flagship language model to follow instructions, making it spit out less unwanted text—but there's still a way to go.
A horrifying new AI app swaps women into porn videos with a click
Deepfake researchers have long feared the day this would arrive.
We can’t afford to stop solar geoengineering research
It is the wrong time to take this strategy for combating climate change off the table.
Meet Altos Labs, Silicon Valley’s latest wild bet on living forever
Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.